CNDO – TSO Misses Primary and Second Endpoints in TRUST-I Crohn’s Study – Coronado announced disappointing TRUST-I results in Crohn’s disease. The trial missed both key endpoints – the primary endpoint was a change in CDAI score of >100 and the key secondary measure of remission, defined as achieving CDAI 150 points. In the corresponding […]
CNDO – TRUST-1 Fully Enrolled (And Then Some) On Schedule, The Clock Is Set – CNDO Now Under BUY LIMIT. Coronado announced completion of enrollment of TRUST-I, its Phase II clinical trial with TSO (Trichuris suis ova or CNDO-201) in 250 Crohn’s disease patients. As expected, top-line data is expected in the fourth quarter – […]
Coronado announced the initiation of an investigator-sponsored pilot study to evaluate CNDO-201 (TSO) for the treatment of moderate-to-severe psoriasis. This is first new TSO study since Harlan Weisman joined the Company as CEO in early January. As a reminder, Weisman led the development of Remicade, JNJ’s best-selling product and approved for several of the same indications […]
CNDO signed an R&D, joint ownership and exclusive license agreement with Freie Universität Berlin for the identification and evaluation of secretory proteins from Trichuris suis. By collaborating with Dr. Susanne Hartman, one of the world leaders in parasitology, the deal extends Coronado’s research into TSO (Trichuris suis ova or CNDO-201).
Our #1 pick for 2013 We met with Coronado Biosciences’ new CEO Harlan Weisman during JP Morgan. We have known Dr. Weisman since our days as a Centocor analyst in the 1990s where he was Chief Medical Officer and subsequently became Senior management at Johnson & Johnson (JNJ) after its acquisition of CNTO. With his […]
Coronado Biosciences is poised for a big year in 2013. Every year we are asked to give our top pick for the year by various publications such as Dick Davis Digest. This year we chose CNDO as our Top Pick for 2013. The company has had two pieces of good news since the last Issue. The […]